Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities
Document Type
Journal Article
Publication Date
1-27-2023
Journal
Expert opinion on drug delivery
DOI
10.1080/17425247.2023.2168641
Keywords
De-risking strategies; Microarray patches; coverage and equity; microneedle patches; pandemic preparedness; pilot manufacturing facilities; product development; vaccine delivery; vaccine development incentives; vaccine manufacturing
Abstract
INTRODUCTION: There is a need for investment in manufacturing for vaccine microarray patches (vMAPs) to accelerate vMAP development and access. vMAPs could transform vaccines deployment and reach to everyone, everywhere. AREAS COVERED: We outline vMAPs' potential benefits for epidemic preparedness and for outreach in low- and lower-middle-income countries (LMICs), share lessons learned from pandemic response, and highlight that investment in manufacturing-at-risk could accelerate vMAP development. EXPERT OPINION: Pilot manufacturing capabilities are needed to produce clinical trial material and enable emergency response. Funding vMAP manufacturing scale-up in parallel to clinical proof-of-concept studies could accelerate vMAP approval and availability. Incentives could mitigate the risks of establishing multi-vMAP manufacturing facilities early.
APA Citation
Scarnà, Tiziana; Menozzi-Arnaud, Marion; Friede, Martin; DeMarco, Kerry; Plopper, George; Hamer, Melinda; Chakrabarti, Ajoy; Gilbert, Philippe Alexandre; Jarrahian, Courtney; Mistilis, Jessica; Hesselink, Renske; Gandrup-Marino, Kristoffer; Amorij, Jean-Pierre; and Giersing, Birgitte, "Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities" (2023). GW Authored Works. Paper 2234.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/2234
Department
Emergency Medicine